Acute-phase response in chronic urticaria

Journal of the European Academy of Dermatology and Venereology

Volumn 26, Issue 6, 2012, Pages 665-672

  Kasperska Zajac, A ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; ANTIINFLAMMATORY AGENT; BIOLOGICAL MARKER; BRADYKININ; C REACTIVE PROTEIN; CYTOKINE; D DIMER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIN DEGRADATION PRODUCT; FIBRINOGEN; GELATINASE B; HAPTOGLOBIN; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 1; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; PLACEBO; PRASTERONE SULFATE; PROTHROMBIN ANTIBODY; PROTHROMBIN FRAGMENT F1; PROTHROMBIN FRAGMENT F2; RECOMBINANT INTERLEUKIN 6; SERUM AMYLOID A; STEROID; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE PHASE RESPONSE; ANGIONEUROTIC EDEMA; ANTIINFLAMMATORY ACTIVITY; BACTERIAL INFECTION; BASOPHIL; BLOOD CLOTTING; BLOOD SAMPLING; CD4+ T LYMPHOCYTE; CHRONIC URTICARIA; CLINICAL ASSESSMENT; CLINICAL TRIAL (TOPIC); CYTOKINE PRODUCTION; DIAGNOSTIC TEST; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EOSINOPHIL; EVIDENCE BASED MEDICINE; FATIGUE; FEVER; FIBRINOGEN BLOOD LEVEL; FIBRINOLYSIS; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HISTOPATHOLOGY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MAST CELL DEGRANULATION; MEDIATOR; MONOCYTE; NEUTROPHIL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEPTOR UPREGULATION; REMISSION; REVIEW; RISK FACTOR; SKIN; STRESS; SYMPTOM; VIRUS INFECTION;

ACUTE-PHASE REACTION; BLOOD COAGULATION; C-REACTIVE PROTEIN; CHRONIC DISEASE; DEHYDROEPIANDROSTERONE SULFATE; FIBRINOLYSIS; HUMANS; INTERLEUKIN-6; MATRIX METALLOPROTEINASE 9; URTICARIA;

EID: 84861571855     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2011.04366.x     Document Type: Review

References (68)

1. Streetz KL, Wüstefeld T, Klein C, Manns MP, Trautwein C,. Mediators of inflammation and acute phase response in the liver. Cell Mol Biol (Noisy-le-grand) 2001; 47: 661-673.
2. Moshage H,. Cytokines and the hepatic acute phase response. J Pathol 1997; 181: 257-266.
3. Gabay C, Kushner I,. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340: 448-454.
4. Gabay C,. Interleukin-6 and chronic inflammation. Arthritis Res Ther 2006; 2: S3.
5. Volanakis JE,. Human C-reactive protein: expression, structure, and function. Mol Immunol 2001; 38: 189-197.
6. Kaplan MH, Volanakis JE,. Interactions of C-reactive protein complexes with the complement system. I. Consumption of human complement associated with the reaction of C-reactive protein with pneumococcal C-polysaccharide and with the choline phosphatides, lecithin and sphingomyelin. J Immunol 1974; 112: 2135-2147.
7. Siegel J, Rent R, Gewurz H,. Interactions of C-reactive protein with the complement system. I. Protamine-induced consumption of complement in acute phase sera. J Exp Med 1974; 140: 631-647.
8. Pepys MB, Lanham JG, De Beer FC,. C-reactive protein in SLE. Clin Rheum Dis 1982; 8: 91-103.
9. Pepys MB, Hirschfield GM,. C-reactive protein: a critical update. J Clin Invest 2003; 111: 1805-1812.
10. Kaplan A,. Inflammation in chronic urticaria is not limited to the consequences of mast cell (or basophil) degranulation. Clin Exp Allergy 2010; 40: 834-835.
11. Natbony SF, Phillips ME, Elias JM, Godfrey HP, Kaplan AP,. Histologic studies of chronic idiopathic urticaria. J Allergy Clin Immunol 1983; 71: 177-183.
12. Kaplan AP,. Chronic urticaria: pathogenesis and treatment. J Allergy Clin Immunol 2004; 114: 465-474.
13. Tedeschi A, Asero R, Lorini M, Marzano AV, Cugno M,. Plasma levels of matrix metalloproteinase-9 in chronic urticaria patients correlate with disease severity and C-reactive protein but not with circulating histamine-releasing factors. Clin Exp Allergy 2010; 40: 875-881.
14. Takahagi S, Mihara S, Iwamoto K, et al. Coagulation/fibrinolysis and inflammation markers are associated with disease activity in patients with chronic urticaria. Allergy 2010; 65: 649-656.
15. Asero R, Cugno M, Tedeschi A,. Activation of blood coagulation in plasma from chronic urticaria patients with negative autologous plasma skin test. J Eur Acad Dermatol Venereol 2011; 25: 201-205.
16. Kasperska-Zajac A, Sztylc J, Machura E, Jop G,. Plasma IL-6 concentration correlates with clinical disease activity and serum C-reactive protein concentration in chronic urticaria patients. Clin Exp Allergy 2011; 41: 1386-1391.
17. Vickers MA, Green FR, Terry C, et al. Genotype at a promoter polymorphism of the interleukin-6 gene is associated with baseline levels of plasma C-reactive protein. Cardiovasc Res 2002; 53: 1029-1034.
18. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350: 1387-1397.
19. Kasperska-Zajac A, Brzoza Z, Rogala B,. Plasma concentration of interleukin 6 (IL-6), and its relationship with circulating concentration of dehydroepiandrosterone sulfate (DHEA-S) in patients with chronic idiopathic urticaria. Cytokine 2007; 39: 142-146.
20. Dos Santos JC, Azor MH, Nojima VY, et al. Increased circulating pro-inflammatory cytokines and imbalanced regulatory T-cell cytokines production in chronic idiopathic urticaria. Int Immunopharmacol 2008; 8: 1433-1440.
21. Daschner A, Rodero M, DE Frutos C, et al. Different serum cytokine levels in chronic vs. acute Anisakis simplex sensitization-associated urticaria. Parasite Immunol 2011; 33: 357-362.
22. Kasperska-Zajac A, Jasinska T, Grzanka A, Kowalik-Sztylc A,. Markers of systemic inflammation in delayed pressure urticaria. Int J Dermatol 2011; doi:.
23. Magen E, Mishal J, Zeldin Y, et al. Increased mean platelet volume and C-reactive protein levels in patients with chronic urticaria with a positive autologous serum skin test. Am J Med Sci 2010; 339: 504-508.
24. Bas M, Hoffmann TK, Bier H, Kojda G,. Increased C-reactive protein in ACE-inhibitor-induced angioedema. Br J Clin Pharmacol 2005; 59: 233-238.
25. Taki M, Watanabe H, Hasegawa T, Bamba H, Shimada T, Hisa Y,. Angioedema: 6 years experience with fourteen cases. Auris Nasus Larynx 2010; 37: 199-204.
26. Hamid Q, Barkans J, Meng Q, et al. Human eosinophils synthesize and secrete interleukin-6, in vitro. Blood 1992; 80: 1496-1501.
27. Seder RA, Paul WE, Ben-Sasson SZ, et al. Production of interleukin-4 and other cytokines following stimulation of mast cell lines and in vivo mast cells/basophils. Int Arch Allergy Appl Immunol. 1991; 94: 137-140.
28. Oishi K, Machida K,. Some plasma component is essential for IL-6 secretion by neutrophils. Environ Health Prev Med 1997; 2: 89-92.
29. Krüger-Krasagakes S, Möller A, Kolde G, Lippert U, Weber M, Henz BM,. Production of interleukin-6 by human mast cells and basophilic cells. J Invest Dermatol 1996; 106: 75-79.
30. Nettis E, Dambra P, Loria MP, et al. Mast-cell phenotype in urticaria. Allergy 2001; 56: 915.
31. Fujii K, Ohgou N,. Up-regulation of IL-6 mRNA in peripheral blood mononuclear cells of patients with acute urticaria. J Dermatol 2004; 31: 242-243.
32. Wedi B, Raap U, Wieczorek D, Kapp A,. Urticaria and infections. Allergy Asthma Clin Immunol 2009; 5: 10.
33. Federman DG, Kirsner RS, Moriarty JP, Concato J,. The effect of antibiotic therapy for patients infected with Helicobacter pylori who have chronic urticaria. J Am Acad Dermatol 2003; 49: 861-864.
34. Shakouri A, Compalati E, Lang DM, Khan DA,. Effectiveness of helicobacter pylori eradication in chronic urticaria: evidence-based analysis using the Grading of Recommendations Assessment, Development, and Evaluation system. Curr Opin Allergy Clin Immunol 2010; 10: 362-369.
35. Stettin D, Waldmann A, Ströhle A, Hahn A,. Association between Helicobacter pylori-infection, C-reactive protein and status of B vitamins. Adv Med Sci 2008; 53: 205-213.
36. Kasperska-Zajac A,. Does dehydroepiandrosterone influence the expression of urticaria?-a mini review. Inflammation 2011; 34: 362-366.
37. Papanicolaou D, Wilder R, Manolagas S, Chrousos G,. The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med 1998; 128: 127-137.
38. Lutgendorf SK, Garand L, Buckwalter KC, Reimer TT, Hong SY, Lubaroff DM,. Life stress, mood disturbance, and elevated interleukin-6 in healthy older women. J Gerontol A Biol Sci Med Sci 1999; 54: M434-M439.
39. Theoharides TC,. The mast cell: a neuroimmunoendocrine master player. Int J Tissue React 1996; 18: 1-21.
40. Pepys MB, Baltz ML,. Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Adv Immunol 1983; 34: 141-212.
41. Lagrand WK, Niessen HW, Wolbink GJ, et al. C-reactive protein colocalizes with complement in human hearts during acute myocardial infarction. Circulation 1997; 95: 97-103.
42. Griselli M, Herbert J, Hutchinson WL, et al. C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med 1999; 190: 1733-1740.
43. Ferrer M, Nakazawa K, Kaplan AP,. Complement dependence of histamine release in chronic urticaria. J Allergy Clin Immunol 1999; 104: 169-172.
44. Xing Z, Gauldie J, Cox G, et al. IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest 1998; 101: 311-320.
45. Maruo N, Morita I, Shirao M, Murota S,. IL-6 increases endothelial permeability in vitro. Endocrinology 1992; 131: 710-714.
46. Asero R, Tedeschi A, Riboldi P, Cugno M,. Plasma of patients with chronic urticaria shows signs of thrombin generation, and its intradermal injection causes wheal-and-flare reactions much more frequently than autologous serum. J Allergy Clin Immunol 2006; 117: 1113-1117.
47. Asero R, Tedeschi A, Coppola R, et al. Activation of the tissue pathway of blood coagulation in patients with chronic urticaria. J Allergy Clin Immunol 2007; 119: 705-710.
48. Asero R, Tedeschi A, Riboldi P, Griffini S, Bonanni E, Cugno M,. Severe chronic urticaria is associated with elevated plasma levels of D-dimer. Allergy 2008; 63: 176-180.
49. Cugno M, Marzano AV, Asero R, Tedeschi A,. Activation of blood coagulation in chronic urticaria: pathophysiological and clinical implications. Intern Emerg Med 2010; 5: 97-101.
50. Kasperska-Zajac A, Jasinska T,. Analysis of plasma D-dimer concentration in patients with delayed pressure urticaria. J Eur Acad Dermatol Venereol 2011; 25: 232-234.
51. Cugno M, Tedeschi A, Crosti C, Marzano AV,. Activation of blood coagulation in autoimmune skin disorders. Expert Rev Clin Immunol 2009; 5: 605-613.
52. Takeda T, Sakurai Y, Takahagi S, et al. Increase of coagulation potential in chronic spontaneous urticaria. Allergy 2011; 66: 428-433.
53. Esmon CT,. Does inflammation contribute to thrombotic events? Haemostasis 2000; 30 (Suppl. 2): 34-40.
54. Path G, Bornstein SR, Ehrhart-Bornstein M, Scherbaum WA,. Interleukin-6 and the interleukin-6 receptor in the human adrenal gland: expression and effects on steroidogenesis. J Clin Endocrinol Metab 1997; 82: 2343-2349.
55. Kessel A, Bishara R, Amital A, et al. Increased plasma levels of matrix metalloproteinase-9 are associated with the severity of chronic urticaria. Clin Exp Allergy 2005; 35: 221-225.
56. Altrichter S, Boodstein N, Maurer M,. Matrix metalloproteinase-9: a novel biomarker for monitoring disease activity in patients with chronic urticaria patients? Allergy 2009; 64: 652-656.
57. Ferrer M, Luquin E, Sanchez-Ibarrola A, Moreno C, Sanz ML, Kaplan AP,. Secretion of cytokines, histamine and leukotrienes in chronic urticaria. Int Arch Allergy Immunol 2002; 129: 254-260.
58. Caproni M, Cardinali C, Giomi B, et al. Serological detection of eotaxin, IL-4, IL-13, IFN-gamma, MIP-1alpha, TARC and IP-10 in chronic autoimmune urticaria and chronic idiopathic urticaria. J Dermatol Sci 2004; 36: 57-59.
59. Tedeschi A, Lorini M, Suli C, Asero R,. Serum interleukin-18 in patients with chronic ordinary urticaria: association with disease activity. Clin Exp Dermatol 2007; 32: 568-570.
60. Tedeschi A, Lorini M, Suli C, Asero R,. No evidence of tumor necrosis factor-alpha release in blood of patients with chronic urticaria. Allergy 2006; 61: 510-511.
61. Raap U, Wieczorek D, Gehring M, et al. Increased levels of serum IL-31 in chronic spontaneous urticaria. Exp Dermatol 2010; 19: 464-466.
62. Piconi S, Trabattoni D, Iemoli E, et al. Immune profiles of patients with chronic idiopathic urticaria. Int Arch Allergy Immunol 2002; 128: 59-66.
63. Asero R, Tedeschi A,. Usefulness of a short course of oral prednisone in antihistamine-resistant chronic urticaria: a retrospective analysis. J Investig Allergol Clin Immunol 2010; 20: 386-390.
64. Papanicolaou DA, Petrides JS, Tsigos C, et al. Exercise stimulates interleukin-6 secretion: inhibition by glucocorticoids and correlation with catecholamines. Am J Physiol 1996; 271: E601-E605.
65. Breuninger LM, Dempsey WL, Uhl J, Murasko DM,. Hydrocortisone regulation of interleukin-6 protein production by a purified population of human peripheral blood monocytes. Clin Immunol Immunopathol 1993; 69: 205-214.
66. Hernández-Rodríguez J, García-Martínez A, Casademont J, et al. A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant-cell arteritis. Arthritis Rheum 2002; 47: 29-35.
67. Ohtsuka T,. Response to oral cyclosporine therapy and high sensitivity-CRP level in chronic idiopathic urticaria. Int J Dermatol 2010; 49: 579-584.
68. Fujii K, Konishi K, Kanno Y, Ohgou N,. Acute urticaria with elevated circulating interleukin-6 is resistant to anti-histamine treatment. J Dermatol 2001; 28: 248-250.